Itolizumab [Bmab 600]
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Erythematosus
Conditions
Lupus Erythematosus, Lupus Nephritis
Trial Timeline
Oct 1, 2019 โ Jan 18, 2024
NCT ID
NCT04128579About Itolizumab [Bmab 600]
Itolizumab [Bmab 600] is a phase 1 stage product being developed by Biocon for Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT04128579. Target conditions include Lupus Erythematosus, Lupus Nephritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04128579 | Phase 1 | Completed |
Competing Products
20 competing products in Lupus Erythematosus